Scholarlink

<p>Aberrant DNA methylation is prevalent in acute lymphoblastic leukemia (ALL), particularly in adult cases, where abnormally high methylation levels correlate significantly with patient age and survival outcomes. Indeed, older patients are more frequently classified into high-risk subgroups due to gene dysfunction driven by aberrant methylation, highlighting its prognostic value. Thus, DNA methylation serves as a valuable prognostic marker for adult patients and supports the therapeutic use of hypomethylating agents (HMAs). In this review, we summarize the latest insights into DNA methylation and its regulation in the context of adult B-ALL and outline the potential clinical application of HMAs for adult patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aberrant DNA methylation in adult B-cell acute lymphoblastic leukemia and the therapeutic potential of hypomethylating agents

  • 期刊论文

  • 发表日期：

    2025年4月3日

查看全文
  • Haiyu Song,
  • Li Yu

摘要

Aberrant DNA methylation is prevalent in acute lymphoblastic leukemia (ALL), particularly in adult cases, where abnormally high methylation levels correlate significantly with patient age and survival outcomes. Indeed, older patients are more frequently classified into high-risk subgroups due to gene dysfunction driven by aberrant methylation, highlighting its prognostic value. Thus, DNA methylation serves as a valuable prognostic marker for adult patients and supports the therapeutic use of hypomethylating agents (HMAs). In this review, we summarize the latest insights into DNA methylation and its regulation in the context of adult B-ALL and outline the potential clinical application of HMAs for adult patients.